Psyence BioMed to manufacture ibogaine in Texas with Benuvia

Psyence BioMed partners with Benuvia for ibogaine production

Psyence BioMed, through its subsidiary Texas Ibogaine Research Corporation (TIRC), has entered a manufacturing agreement with Benuvia Operations to produce pharmaceutical-grade ibogaine in the United States, according to a recent announcement. The collaboration aims to establish a manufacturing pathway in Texas, leveraging Benuvia's DEA-registered facility in Round Rock.

Manufacturing capabilities and regulatory context

Benuvia's facility, spanning 83,000 square feet, is equipped for the development and commercial-scale production of controlled substances, including ibogaine. This partnership builds on TIRC's exclusive U.S. license agreement with PsyLabs for ibogaine supply. Benuvia currently holds about half of the U.S. production quota for ibogaine, positioning it as a key player in the domestic manufacturing landscape. The company is advancing applications for necessary DEA permits to facilitate production.

Strategic implications for Psyence BioMed

The partnership with Benuvia is a strategic move by Psyence BioMed to create an integrated U.S. supply chain and regulatory platform for ibogaine. The company aims to support future clinical and regulatory submissions by establishing a reliable manufacturing base. This initiative is part of a broader effort to develop ibogaine-based therapies for conditions like opioid use disorder and mental health issues affecting veterans.

Why it matters

The establishment of a U.S.-based manufacturing pathway for ibogaine is significant due to the limited domestic production capacity for this substance. By partnering with Benuvia, Psyence BioMed is poised to enhance its research and clinical development capabilities, potentially leading to new therapeutic options for patients with unmet medical needs. The collaboration also underscores the importance of regulatory compliance and manufacturing standards in advancing neuroplastogen-based treatments.

Psyence BioMed's efforts reflect a growing interest in exploring nature-derived compounds for therapeutic use, although regulatory hurdles remain. The company continues to focus on evidence-based approaches to develop safe and effective treatments.